10mM in DMSO per flussi di lavoro cromatografici e analitici sensibili che richiedono un'interferenza minima della linea di base.
Desiccated,Store at -80°C Spedizione Dry ice packs + Cold packs. Consultare il COA specifico del lotto per le specifiche esatte.
SDS, COA, scheda tecnica e scheda delle specifiche disponibili per il download. COA specifico del lotto accessibile tramite ricerca per numero di lotto.
Citato in 0 pubblicazioni peer-reviewed su cromatografia, sintesi organica e reazioni di accoppiamento incrociato.
XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC 50 s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1 ，MMP-2， MMP-3 ，MMP-8，MMP-9， MMP-13 ，respectively.
In Vitro
XL-784 is a highly potent, low-molecular-weight (1,122 g/mol) inhibitor of MMPs that has very limited aqueous solubility (20 μg/mL). XL-784 potently inhibits MMP-2, MMP-13, and\nADAM10 [TNF-α-converting enzyme (TACE)] activity in vitro, with IC 50 values in the range of 1-2 nM. XL-784 also inhibits MMP-9 (IC 50 ~20 nM) activity and ADAM17 (IC 50 ~70 nM) also known as TACE. However, it exhibits low potency for inhibition of MMP-1 (IC 50 ~2,000 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
All mice tolerate the treatments similarly. Control mice all developed aneurysms with a mean %△AD of 158.5%±4.3%. Treatment with all doses of XL-784 and doxycycline are effective in inhibiting aortic dilatation. There is a clear dose-response relationship between XL-784 and reductions in aortic dilatation at harvest (50 mg/kg 140.4% ±3.2%; 125 mg/kg 129.3% ±5.1%; 250 mg/kg 119.2%±3.5%; all Ps <0.01 compared to control). This continues with the higher doses (375 mg/kg 88.6%±4.4%; 500 mg/kg 76.0%±3.5%). The highest 2 doses of XL-784 tested are more effective than doxycycline (112.2%±2.0%, P<0.05) in inhibiting maximal dilatation of the aorta after elastase perfusion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice A total of 89 mice undergo aortic perfusion. Beginning the day of perfusion, animals are treated with the study drug (e.g., XL-784), a negative control, or doxycycline. 76 animals survive to sacrifice and are included in the analysis. Animals treated with the experimental agent, XL-784 , receive gavage daily with the agent diluted in 0.1 mL of Cremophor, a nonionic castor oil-based solubilizer and emulsifying agent. Three doses of the drug are used, 50 (n=17), 125 (n=17), and 250 mg/kg per d (n=18) administered as a single daily dose. The fifth group of mice do not receive a gavage treatment but are treated with doxycycline (n=19) in their drinking water at a concentration 100 mg/kg per d of the animals. In the second treatment protocol, a total of 50 animals underwent aortic perfusion and 47 animals survive for analysis at 14 days. The 5 treatment groups are XL-784 at 250, 375, or 500 mg/kg , Cremaphor diluent alone, or doxycycline 100 mg/kg. Animals are assigned in groups of 3 to a treatment group rotating randomly through each treatment group until there are 9 animals in each group except for the 500 mg/kg per d group which totaled to 14 animals . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:MMP-2 0.81 nM (IC 50 ) MMP13 0.56 nM (IC 50 ) MMP-8 10.8 nM (IC 50 ) MMP-9 18 nM (IC 50 ) MMP-3 120 nM (IC 50 ) MMP-1 1900 nM (IC 50 )
Documento completo su pericoli, manipolazione, stoccaggio e conformità normativa.
<<<<<<< HEAD Scarica SDS → ======= Scarica SDS → >>>>>>> release248-p3Dati di qualità specifici del lotto. Inserisci il numero di lotto per recuperare il COA esatto.
Cerca COA →Riepilogo di riferimento rapido delle specifiche e applicazioni del prodotto.
Visualizza scheda tecnica →Attributi di qualità completi e criteri di accettazione per questa qualità.
Visualizza scheda delle specifiche →